Pàgina inicial > Resultats de la cerca: Armstrong, April
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 4 registres trobats en 0.02 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
18 p, 951.7 KB Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis : A Network Meta-Analysis / Armstrong, April W (Department of Dermatology. Keck School of Medicine. University of Southern California) ; Soliman, A.M. (AbbVie. Inc.) ; Betts, Keith A (Analysis Group. Inc.) ; Wang, Y. (Analysis Group. Inc.) ; Gao, Y. (Analysis Group. Inc.) ; Stakias, V. (AbbVie. Inc.) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Introduction: The long-term benefit-risk profiles of licensed and investigational treatments for moderate-to-severe plaque psoriasis have not been fully characterized. Methods: Randomized controlled trials (RCTs) of licensed and investigational treatments for moderate-to-severe plaque psoriasis were identified through a systematic literature review through 2 May 2021. [...]
2022 - 10.1007/s13555-021-00647-0
Dermatology and Therapy, Vol. 12 Núm. 1 (january 2022) , p. 167-184  
Registre complet - Creative Commons
2.
4 p, 172.8 KB A Response to : Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis / Armstrong, April W. (University of Southern California. Department of Dermatology) ; Soliman, Ahmed M. (AbbVie, Inc) ; Betts, Keith A. (Analysis Group, Inc) ; Wang, Yan (Analysis Group, Inc) ; Gao, Yawen (Analysis Group, Inc) ; Stakias, Vassilis (AbbVie, Inc) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
2022 - 10.1007/s13555-022-00812-z
Dermatology and Therapy, Vol. 12 (october 2022) , p. 2867-2870  
Registre complet - Creative Commons
3.
21 p, 1000.2 KB Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis : A Network Meta-analysis / Armstrong, April W. (University of Southern California. Department of Dermatology, Keck School of Medicine) ; Soliman, Ahmed M. (AbbVie, Inc) ; Betts, Keith A. (Analysis Group, Inc) ; Wang, Yan (Analysis Group, Inc) ; Gao, Yawen (Analysis Group, Inc) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ; Universitat Autònoma de Barcelona
The clinical benefits of biologic and oral treatments for moderate-to-severe plaque psoriasis are well-established, but efficacy outcomes can vary across therapies. Comparative efficacy analysis can be highly informative in clinical settings with multiple therapeutic options. [...]
2021 - 10.1007/s13555-021-00511-1
Dermatology and Therapy, Vol. 11 (march 2021) , p. 885-905  
Registre complet - Creative Commons
4.
18 p, 504.6 KB Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure / Armstrong, April W (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ; Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Boehncke, Wolf-Henning (University of Geneva. Department of Pathology and Immunology) ; Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ; Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ; Papp, Kim (K Papp Clinical Research and Probity Medical Research) ; Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ; Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ; Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ; Renda, Lisa (Eli Lilly and Company) ; Agada, Noah (Eli Lilly and Company) ; Xu, Wen (Eli Lilly and Company) ; Gallo, Gaia (Eli Lilly and Company) ; Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ; Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
93 Armstrong, A.
2 Armstrong, Alexander
2 Armstrong, April W
3 Armstrong, April W.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem